Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature

Piet Ost, Alberto Bossi, Karel Decaestecker, Gert De Meerleer, Gianluca Giannarini, Robert Jeffrey Karnes, Mack Roach, Alberto Briganti

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Context The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. Objective To perform a systematic review of MDT for oligometastatic PCa recurrence. Evidence acquisition This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or toxicity or complications of MDT (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. Evidence synthesis Fifteen single-arm case series reporting on a total of 450 patients met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic PCa recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the patients (98%). Nodal, bone, and visceral metastases were treated in 78%, 21%, and 1%, respectively. Patients were treated with either RT (66%) or lymph node dissection (LND) (34%). Adjuvant androgen deprivation was given in 61% of patients (n = 275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49% of patients (n = 172). Overall, 51% of patients were progression free 1-3 yr after salvage MDT, with most of them receiving adjuvant treatment. For RT, grade 2 toxicity was observed in 8.5% of patients, with one case of grade 3 toxicity. In the case of LND, 11% and 12% of grade 2 and grade 3 complications, respectively, were reported. Conclusions MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. Patient summary We performed a systematic review to assess complications and outcomes of treating oligometastatic prostate cancer recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials.

Original languageEnglish (US)
Pages (from-to)852-863
Number of pages12
JournalEuropean Urology
Volume67
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Prostatic Neoplasms
Neoplasm Metastasis
Recurrence
Radiotherapy
Therapeutics
Lymph Node Excision
Standard of Care
Positron-Emission Tomography
Androgens
Meta-Analysis
Randomized Controlled Trials
Tomography
Databases
Guidelines
Bone and Bones

Keywords

  • Lymph node excision
  • Neoplasm metastasis
  • Neoplasm recurrence
  • Prostatic neoplasms
  • Radiosurgery

ASJC Scopus subject areas

  • Urology

Cite this

Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer : A systematic review of the literature. / Ost, Piet; Bossi, Alberto; Decaestecker, Karel; De Meerleer, Gert; Giannarini, Gianluca; Karnes, Robert Jeffrey; Roach, Mack; Briganti, Alberto.

In: European Urology, Vol. 67, No. 5, 01.05.2015, p. 852-863.

Research output: Contribution to journalArticle

Ost, Piet ; Bossi, Alberto ; Decaestecker, Karel ; De Meerleer, Gert ; Giannarini, Gianluca ; Karnes, Robert Jeffrey ; Roach, Mack ; Briganti, Alberto. / Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer : A systematic review of the literature. In: European Urology. 2015 ; Vol. 67, No. 5. pp. 852-863.
@article{7f2fa2531e8f467da3833b507e608fec,
title = "Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature",
abstract = "Context The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. Objective To perform a systematic review of MDT for oligometastatic PCa recurrence. Evidence acquisition This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or toxicity or complications of MDT (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. Evidence synthesis Fifteen single-arm case series reporting on a total of 450 patients met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic PCa recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the patients (98{\%}). Nodal, bone, and visceral metastases were treated in 78{\%}, 21{\%}, and 1{\%}, respectively. Patients were treated with either RT (66{\%}) or lymph node dissection (LND) (34{\%}). Adjuvant androgen deprivation was given in 61{\%} of patients (n = 275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49{\%} of patients (n = 172). Overall, 51{\%} of patients were progression free 1-3 yr after salvage MDT, with most of them receiving adjuvant treatment. For RT, grade 2 toxicity was observed in 8.5{\%} of patients, with one case of grade 3 toxicity. In the case of LND, 11{\%} and 12{\%} of grade 2 and grade 3 complications, respectively, were reported. Conclusions MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. Patient summary We performed a systematic review to assess complications and outcomes of treating oligometastatic prostate cancer recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials.",
keywords = "Lymph node excision, Neoplasm metastasis, Neoplasm recurrence, Prostatic neoplasms, Radiosurgery",
author = "Piet Ost and Alberto Bossi and Karel Decaestecker and {De Meerleer}, Gert and Gianluca Giannarini and Karnes, {Robert Jeffrey} and Mack Roach and Alberto Briganti",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.eururo.2014.09.004",
language = "English (US)",
volume = "67",
pages = "852--863",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer

T2 - A systematic review of the literature

AU - Ost, Piet

AU - Bossi, Alberto

AU - Decaestecker, Karel

AU - De Meerleer, Gert

AU - Giannarini, Gianluca

AU - Karnes, Robert Jeffrey

AU - Roach, Mack

AU - Briganti, Alberto

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Context The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. Objective To perform a systematic review of MDT for oligometastatic PCa recurrence. Evidence acquisition This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or toxicity or complications of MDT (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. Evidence synthesis Fifteen single-arm case series reporting on a total of 450 patients met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic PCa recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the patients (98%). Nodal, bone, and visceral metastases were treated in 78%, 21%, and 1%, respectively. Patients were treated with either RT (66%) or lymph node dissection (LND) (34%). Adjuvant androgen deprivation was given in 61% of patients (n = 275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49% of patients (n = 172). Overall, 51% of patients were progression free 1-3 yr after salvage MDT, with most of them receiving adjuvant treatment. For RT, grade 2 toxicity was observed in 8.5% of patients, with one case of grade 3 toxicity. In the case of LND, 11% and 12% of grade 2 and grade 3 complications, respectively, were reported. Conclusions MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. Patient summary We performed a systematic review to assess complications and outcomes of treating oligometastatic prostate cancer recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials.

AB - Context The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. Objective To perform a systematic review of MDT for oligometastatic PCa recurrence. Evidence acquisition This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or toxicity or complications of MDT (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. Evidence synthesis Fifteen single-arm case series reporting on a total of 450 patients met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic PCa recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the patients (98%). Nodal, bone, and visceral metastases were treated in 78%, 21%, and 1%, respectively. Patients were treated with either RT (66%) or lymph node dissection (LND) (34%). Adjuvant androgen deprivation was given in 61% of patients (n = 275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49% of patients (n = 172). Overall, 51% of patients were progression free 1-3 yr after salvage MDT, with most of them receiving adjuvant treatment. For RT, grade 2 toxicity was observed in 8.5% of patients, with one case of grade 3 toxicity. In the case of LND, 11% and 12% of grade 2 and grade 3 complications, respectively, were reported. Conclusions MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. Patient summary We performed a systematic review to assess complications and outcomes of treating oligometastatic prostate cancer recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials.

KW - Lymph node excision

KW - Neoplasm metastasis

KW - Neoplasm recurrence

KW - Prostatic neoplasms

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84964267911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964267911&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2014.09.004

DO - 10.1016/j.eururo.2014.09.004

M3 - Article

C2 - 25240974

AN - SCOPUS:84964267911

VL - 67

SP - 852

EP - 863

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -